Clinical Trial Update: Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia [Phase 1]

View source ↗

Summary

Phase 1 trial completed evaluating safety and tolerability of a single dose of PF-06741086 in Chinese adults with severe hemophilia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• PF-06741086

Snippet

Sponsor: Pfizer | Conditions: Severe Hemophilia | Phase 1 | Status: COMPLETED | Results posted: 2023-07-07